Document is current
Any future updates will be listed below
-
Authors
Geurts, Birgit S.
Battaglia, Thomas W.
van Berge Henegouwen, J. Maxime
Zeverijn, Laurien J.
de Wit, Gijs F.
Hoes, Louisa R.
van der Wijngaart, Hanneke
van der Noort, Vincent
Roepman, Paul
de Leng, Wendy W. J.
Jansen, Anne M. L.
Opdam, Frans L.
de Jonge, Maja J. A.
Cirkel, Geert A.
Labots, Mariette
Hoeben, Ann
Kerver, Emile D.
Bins, Adriaan D.
Erdkamp, Frans G.L.
van Rooijen, Johan M.
Houtsma, Danny
Hendriks, Mathijs P. http://orcid.org/0000-0001-6687-5393
de Groot, Jan-Willem B.
Verheul, Henk M. W.
Gelderblom, Hans
Voest, Emile E.
- License Information
-
More Information
Article History
Received: 20 December 2022
Accepted: 20 February 2023
First Online: 4 March 2023
Declarations
:
: DRUP was approved by the independent ethics committee and by the institutional review boards in every participating hospital. The study is conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki’s ethical principles for medical research. Written informed consent was obtained from all study subjects.
: Not applicable.
: Emile E.Voest, Henk M.W. Verheul and Hans Gelderblom have, through the DRUP and other studies, received support from pharmaceutical companies participating in the DRUP. Frans L. Opdam reports research funding by Boehringer Ingelheim, AstraZeneca, GSK, Cytovation, InteRNA technologies, Merus, Taiho, Pierre Fabre and Kinnate. Mathijs P. Hendriks reports research funding by Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, Eisai, Ipsen, Merck Sharp & Dohme, Novartis, Pfizer and Roche. Jan-Willem B. de Groot is involved in advisory boards for Pierre Fabre, BMD and MSD. The other authors declare no competing interests.
